November 20, 2018

Doxorubicin (Dox) is an effective anti-cancer drug, but it’s also a very toxic one, causing severe heart and immune damage. The doses needed to impact tumors are not well tolerated by patients; however, researchers may have found an answer through combination therapy. A study published in the journal Cell Biology International has shown that combining Dox with the natural supplement Modified Citrus Pectin (MCP) increases the anti-cancer activity of Dox. This finding bodes well for prostate cancer patients, especially those too weak for normal chemotherapy regimens. Combination therapy may allow for lower doses of Dox with enhanced clinical impact and reduced toxicity.